Eligo Bioscience
Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing.
- biotechnology
- horizon europe
- dt and ls
- spinout
- biotech and pharma
- radar de l'innovation
- tech for business
- eit ecosystem
- observatoire industrial tech
- genetics and genomics
- observatoire deeptech
- eit health
- biotech, medtech and e-health
- observatoire healthtech
- synthetic biology
- participations bpifrance
- microbiome
- gene therapy
- crispr
- bacteria
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 17 % | 646 % | (88 %) | 5980 % | (16 %) | 2 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2084 %) | (721 %) | (8154 %) | (132 %) | (371 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1676 %) | (548 %) | (5562 %) | (80 %) | (269 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Eligo Bioscience is a cutting-edge biotechnology startup that focuses on developing targeted antimicrobial solutions using advanced synthetic biology. The company operates in the healthcare and biotechnology markets, addressing significant unmet medical needs related to the human microbiome—the community of trillions of bacteria living in and on our bodies. These bacteria are increasingly linked to a variety of severe diseases, including cancer, obesity, neurodegenerative diseases, and autoimmune disorders.
Eligo Bioscience's core innovation lies in its proprietary technology called "Eligobiotics." These are genetic circuits engineered to be delivered by bacteriophages—viruses that infect bacteria. These circuits can diagnose, eradicate, or modify specific bacterial populations within the microbiome. This targeted approach allows for precision treatment, minimizing the collateral damage to beneficial bacteria that is often seen with traditional antibiotics.
The company serves a diverse range of clients, including those in human and animal health, cosmetics, industrial biotechnology, and food industries. By addressing both medical and non-medical applications, Eligo Bioscience taps into multiple revenue streams. Their business model revolves around research and development, followed by commercialization of their Eligobiotics technology. They generate income through partnerships, licensing agreements, and direct sales of their products.
Eligo Bioscience has assembled a strong team of scientists, genome architects, and executives to translate their research into real-world applications. This multidisciplinary team is crucial for navigating the complex landscape of synthetic biology and genome engineering.
In summary, Eligo Bioscience is a pioneering company in the field of synthetic biology, focusing on precision microbiome engineering to tackle a wide range of health issues. Their innovative approach and diverse market applications position them as a significant player in the biotech industry.
Keywords: Biotechnology, Synthetic Biology, Microbiome, Antimicrobials, Healthcare, Precision Medicine, Genetic Engineering, Bacteriophages, R&D, Innovation.